

**ADEQUAN I.M.- polysulfated glycosaminoglycan injection, solution  
American Regent, Inc.**

-----  
**adequan polysulphated glycosaminoglycan solution for injection - UK**

**Adequan  
polysulphated glycosaminoglycan**



**NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF  
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH  
RELEASE, IF DIFFERENT**

Marketing Authorisation Holder

Aniserve GmbH  
Geyerspergerstr. 27  
80689 Muenchen  
Germany

Manufacturing Authorisation Holder Responsible for Batch Release

Klifovet GmbH  
Geyerspergerstr. 27  
80689 München  
Germany

**NAME OF THE VETERINARY MEDICINAL PRODUCT**

Adequan 100 mg/ml Solution for Injection

**STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS**

Active Substance:

Polysulphated Glycosaminoglycan (PSGAG) 100 mg/ml  
Clear, colourless to pale yellow aqueous solution.

**INDICATIONS**

For treatment of lameness in horses due to traumatic or degenerative aseptic joint

disease and acute superficial digital flexor tendonitis.

### **CONTRAINDICATIONS**

Do not use in animals with known hypersensitivity to the active ingredient.

Do not use in cases of advanced renal or hepatic disease.

Do not use in pregnant animals.

Any solution remaining in the vial after withdrawal of the required dose should be discarded.

If you notice any serious effect or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

### **ADVERSE REACTIONS**

None known.

### **TARGET SPECIES**

Horse

For animal treatment only

### **DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

The contents of a 5 ml vial are injected by deep intra-muscular injection every four days for a total of seven injections.

### **ADVICE ON CORRECT ADMINISTRATION**

This product does not contain an antimicrobial preservative. Any solution remaining in the vial after withdrawal of the required dose should be discarded.

For single use only.

### **WITHDRAWAL PERIOD**

Meat and offal - Zero days

### **SPECIAL STORAGE PRECAUTIONS**

Keep out of the reach and sight of children.

Do not store above 25 °C.

Protect from light.

Keep the vial in the carton.

Do not use after the expiry date which is stated on the label and carton.

The expiry date refers to the last date of that month.

### **SPECIAL WARNINGS**

### Special precautions for use in animals

For intramuscular administration only.

If signs or symptoms of hypersensitivity occur, the treatment must be discontinued.

### User Warnings

Care should be taken to avoid accidental self-injection.

In the case of accidental eye or skin contact, wash the affected area thoroughly with copious amounts of water. If irritation persists, seek medical attention.

### Interaction with other medicinal products and other forms of interaction

Adequan may potentiate the action of anticoagulant preparations.

### Overdose (symptoms, emergency procedures, antidotes)

In the case of overdosage, blood coagulation time, as measured by activated partial thromboplastin time, may be prolonged for a few hours after the injection.

For Animal Treatment Only

## **SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS**

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

## **OTHER INFORMATION**

The active ingredient is a semisynthetic substance, similar to the physiological mucopolysaccharides which are the basic component of cartilage. In healthy joints, the synthesis and degradation of cartilage is in equilibrium. In traumatic and degenerative joint disease, the natural equilibrium between synthesis and degradation of the cartilage is disturbed. This results in an increased degradation which further results in a loss of glycosaminoglycans.

Adequan inhibits cartilage degrading enzymes (various glycanohydrolases and glycosidases), stimulates the proteoglycan synthesis and hyaluronic acid synthesis and thus increases the viscosity of the synovia.

Various *in-vitro* studies and animal models have been employed to investigate the anti-osteoarthritis activities of PSGAG.

The finding, that the development and progression of degenerative joint diseases were inhibited in all species and models tested, indicates that PSGAG will also therapeutically influence degenerative or traumatic joint diseases in horses.

|               |                              |
|---------------|------------------------------|
| MA Number     | Legal Category               |
| MA 18169/1001 | POM-V To be supplied only on |

Veterinary Medicinal product authorised for use in the UK.



ADEQUAN and the related logos are trademarks of American Regent, Inc.

RQ1121-B

Rev. 03/2025

### **PRINCIPAL DISPLAY PANEL**

#### **Adequan**

polysulphated glycosaminoglycan

**Adequan 100 mg/ml**

**Solution for Injection**

**For intramuscular injection.**

**For treatment of lameness in horses due to traumatic or degenerative  
aspetic joint disease and acute superficial digital flexor tendonitis.**

**7x 5 ml**



## ADEQUAN I.M.

polysulfated glycosaminoglycan injection, solution

### Product Information

|                                |                          |                           |               |
|--------------------------------|--------------------------|---------------------------|---------------|
| <b>Product Type</b>            | PRESCRIPTION ANIMAL DRUG | <b>Item Code (Source)</b> | NDC:10797-995 |
| <b>Route of Administration</b> | INTRAMUSCULAR            |                           |               |

**Active Ingredient/Active Moiety**

| Ingredient Name   | Basis of Strength              | Strength       |
|---|--------------------------------|----------------|
| <b>POLYSULFATED GLYCOSAMINOGLYCAN</b> (UNII: 268AW7000T) (POLYSULFATED GLYCOSAMINOGLYCAN - UNII:268AW7000T) | POLYSULFATED GLYCOSAMINOGLYCAN | 100 mg in 1 mL |

**Inactive Ingredients**

| Ingredient Name                             | Strength |
|---|----------|
| <b>WATER</b> (UNII: 059QF0KO0R)             |          |
| <b>SODIUM HYDROXIDE</b> (UNII: 55X04QC32I)  |          |
| <b>HYDROCHLORIC ACID</b> (UNII: QTT17582CB) |          |
| <b>SODIUM CHLORIDE</b> (UNII: 451W47IQ8X)   |          |

**Packaging**

| # | Item Code        | Package Description | Marketing Start Date | Marketing End Date |
|---|------------------|---------------------|----------------------|--------------------|
| 1 | NDC:10797-995-94 | 7 in 1 CARTON       |                      |                    |
| 1 |                  | 5 mL in 1 VIAL      |                      |                    |

**Marketing Information**

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|--------------------|--|----------------------|--------------------|
| Export only        |  | 10/07/2025           |                    |

**Labeler** - American Regent, Inc. (002033710)**Registrant** - American Regent, Inc. (002033710)

Revised: 5/2026

American Regent, Inc.